Skip to content

Efficacy of Blue Wavelength in Managing Dry Eye

Efficacy of Blue Wavelength in Managing Dry Eye

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04965974
Enrollment
160
Registered
2021-07-16
Start date
2021-07-31
Completion date
2021-08-31
Last updated
2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Disease

Brief summary

The study is conducted to evaluate the efficacy of digital blue light blocking filter in improvement of clinical indices of dry eye and ocular symptoms related to dry eye. Introduction: Dry eye disease is a multifactorial disease of the ocular surface caused by loss of tear film homeostasis resulting damage to the ocular surface and neurosensory abnormalities.

Detailed description

60 subjects aged 20-35 years with ocular surface disease index score greater than 13 will be taken from the University of Faisalabad. After taking consent, procedure starts from history then Schirmer test 1 will be performed to measure the tear deficient dry eye. Tear break up time will be done to assess the evaporative dry eye. Corneal surface staining will be used to measure corneal erosions. OSDI questionnaire will be used for the evaluation of ocular symptoms related to dry eye. The digital blue light blocking filter will be randomly installed in digital devices of the 80 subjects and rest of 80 will be without filter. After baseline data follow ups will be after 3 weeks and second after 8 weeks of filter use. Schirmer test 1, tear break up time corneal surface staining and OSDI will be performed on both groups (filter users and non-filter users) for the evaluation of dry eye. Data will be analyzed using SPSS version 21. Result of this study will give knowledge that use of digital blue light blocking filters are useful in the management of dry eye disease.

Interventions

DEVICEDigital blue light blocking filter

digital blue light blocking filter will be given to 80 dry eye subjects in mobile phones and laptops and 80 individuals will be without filters digital devices users

Sponsors

University of Faisalabad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The digital blue light blocking filter will be randomly installed in digital devices of the 80 subjects and rest of 80 will be without filter.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Females with age 20-35years * using digital devices androids and laptops * Ametropia of up to 1.0 Diopter sphere(DS) and astigmatism of less than 0.5 * Emmetropes.

Exclusion criteria

* Subjects using topical drugs * Smokers * Subjects undergoing dry eye treatment * History of contact lens wear within the past three months * Corneal surface disease other than dry eye * Corneal or eyelid infections * Corneal surgeries * Refractive error of more than 1 DS of SE and astigmatism of greater than0.5DC * Age \<18 and \>3 years * Subjects already using blue light blocking filters * I phone users * Pregnant women * Males

Design outcomes

Primary

MeasureTime frameDescription
tear break up time8 weeksimprovement in evaporative dry eye will be assessed by improvement in tear break up time in seconds after filter use.
Schirmer test values8 weeksimprovement in aqueous deficient dry eye by Schirmer test values in mm .
corneal surface staining8 weeks'corneal surface staining grade scale' assess the improvement corneal surface erosions after filter use

Secondary

MeasureTime frameDescription
ocular surface disease index questionnaire8 weeksimprovement in ocular surface disease index score.13-22ocular surface disease index score mild dry eye ,23-32 score means moderate dry eye and ocular surface disease index greater than 33 indicate severe dry eye .

Countries

Pakistan

Contacts

Primary ContactKomal Atta, mbbs
komal.atta@tuf.edu.pk03224075007
Backup ContactNimra Gul, m.phil od
Nimra.gul@tuf.edu.pk03156673622

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026